New Vernon Capital Holdings II LLC Makes New $122,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

New Vernon Capital Holdings II LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 5,822 shares of the biopharmaceutical company’s stock, valued at approximately $122,000.

Several other hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $65,000. KBC Group NV boosted its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. 79.22% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CPRX has been the topic of several research analyst reports. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, Bank of America reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Trading Up 0.3 %

Shares of CPRX opened at $23.19 on Friday. The stock’s 50-day moving average price is $22.57 and its two-hundred day moving average price is $22.16. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $26.16. The company has a market capitalization of $2.83 billion, a PE ratio of 19.65, a PEG ratio of 3.31 and a beta of 0.79.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.